ConductScience.org, home

Paper32196334

Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia.

Winn BA and 15 others. J Nat Prod, 2020. Cited by 19 papers, by iCite.

Cite this record

ConductScience Library. Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia. Papers, record 32196334. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32196334

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia.
PubMed
Journal
J Nat Prod
PubMed
Year
2020
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
19
iCite
Relative citation ratio, by iCite
0.98
iCite
Revised in PubMed
2025-05-30
PubMed

Authors16

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Winn BABlake A
2Devkota LLaxman
3Kuch BBunnarack
4MacDonough MTMatthew T
5Strecker TETracy E
6Wang YYifan
7Shi ZZhe
8Gerberich JLJeni L
9Mondal DDeboprosad
10Ramirez AJAlejandro J
11Hamel EErnest
12Chaplin DJDavid J
13Davis PPeter
14Mason RPRalph P
15Trawick MLMary Lynn
16Pinney KGKevin Ghttps://orcid.org/0000-0003-1262-8631

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Agents, PhytogenicMajor topic
ProdrugsMajor topic
StilbenesMajor topic
A549 Cells
Animals
Breast Neoplasms
Cell Hypoxia
Colchicine
Drug Screening Assays, Antitumor
Female
Humans
Mice
Mice, Inbred BALB C
NADPH-Ferrihemoprotein Reductase
Tubulin

Source PubMed

Download CSV of topics

Grants5

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R01 CA140674NCI NIH HHSUnited StatesR01CA140674PubMed and NIHNIH RePORTER
S10 RR024757NCRR NIH HHSUnited StatesS10RR024757PubMed and NIHNIH RePORTER
P30 CA142543NCI NIH HHSUnited StatesP30CA142543PubMed and NIHNIH RePORTER
HHSN261200800001CCCR NIH HHSUnited StatesPubMedPubMed
HHSN261200800001ENCI NIH HHSUnited StatesPubMedPubMed

Download CSV of grants

References62

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
1486895Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation.Br J Radiol1979https://conductscience.org/library/papers/486895PubMed
221321746A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment.Integr Biol (Camb)2011https://conductscience.org/library/papers/21321746PubMed
312956893Concept, mechanisms and therapeutics of angiogenesis in cancer and other diseases.J Pharm Pharmacol2003https://conductscience.org/library/papers/12956893PubMed
425264827Biological evaluation of the activity of some benzimidazole-4,7-dione derivatives.Molecules2014https://conductscience.org/library/papers/25264827PubMed
52920809Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4.Experientia1989https://conductscience.org/library/papers/2920809PubMed
63412321Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study.Mol Pharmacol1988https://conductscience.org/library/papers/3412321PubMed
720570444The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents.Cancer Treat Rev2011https://conductscience.org/library/papers/20570444PubMed
823149893Imaging hypoxia to improve radiotherapy outcome.Nat Rev Clin Oncol2012https://conductscience.org/library/papers/23149893PubMed
919125622Tubulin-interactive natural products as anticancer agents.J Nat Prod2009https://conductscience.org/library/papers/19125622PubMed
1022937031Tubulin-destabilizing agent BPR0L075 induces vascular-disruption in human breast cancer mammary fat pad xenografts.PLoS One2012https://conductscience.org/library/papers/22937031PubMed
1117406391Sulforhodamine B colorimetric assay for cytotoxicity screening.Nat Protoc2006https://conductscience.org/library/papers/17406391PubMed
127752190Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6(1a)J Med Chem1995https://conductscience.org/library/papers/7752190PubMed
1322235096Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors.Clin Cancer Res2012https://conductscience.org/library/papers/22235096PubMed
149572894Antineoplastic agents. 379. Synthesis of phenstatin phosphate.J Med Chem1998https://conductscience.org/library/papers/9572894PubMed
1510682679NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line.Br J Cancer2000https://conductscience.org/library/papers/10682679PubMed
1615928673Disrupting tumour blood vessels.Nat Rev Cancer2005https://conductscience.org/library/papers/15928673PubMed
1717459681Vascular damaging agents.Clin Oncol (R Coll Radiol)2007https://conductscience.org/library/papers/17459681PubMed
189537252Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines.Cancer Res1998https://conductscience.org/library/papers/9537252PubMed
1910893310Antineoplastic agents. 443. Synthesis of the cancer cell growth inhibitor hydroxyphenstatin and its sodium diphosphate prodrug.J Med Chem2000https://conductscience.org/library/papers/10893310PubMed
20145057993-substituted-5-aziridinyl-1-methylindole-4,7-diones as NQO1-directed antitumour agents: mechanism of activation and cytotoxicity in vitro.Biochem Pharmacol2003https://conductscience.org/library/papers/14505799PubMed

See all 62 referencesDownload CSV of references

Cited by13

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 19 citations.

PMIDTitleJournalYearIn PapersSource
42792253Engineering a Redox-Responsive Bimolecular Prodrug for Targeted Gastric Cancer Combination Therapy: Design, Synthesis, and In Vivo Evaluation.Antioxidants (Basel)2026https://conductscience.org/library/papers/42792253PubMed
40927638Targeting Tumor-Associated Hypoxia with Bioreductively Activatable Prodrug Conjugates Derived from Dihydronaphthalene, Benzosuberene, and Indole-based Inhibitors of Tubulin Polymerization.RSC Med Chem2025https://conductscience.org/library/papers/40927638PubMed
40535125Research progress on the cross-regulation between ferroptosis and immunogenic cell death in tumor micro-environment.Front Oncol2025https://conductscience.org/library/papers/40535125PubMed
39124883Recent Advances in the Application of Nitro(het)aromatic Compounds for Treating and/or Fluorescent Imaging of Tumor Hypoxia.Molecules2024https://conductscience.org/library/papers/39124883PubMed
38026524Preparation and Characterization Evaluation of Poly(L-Glutamic Acid)-g-Methoxy Poly(Ethylene Glycol)/Combretastatin A4/BLZ945 Nanoparticles for Cervical Cancer Therapy.Int J Nanomedicine2023https://conductscience.org/library/papers/38026524PubMed
37984295Synthesis and biological evaluation of structurally diverse 6-aryl-3-aroyl-indole analogues as inhibitors of tubulin polymerization.Eur J Med Chem2024https://conductscience.org/library/papers/37984295PubMed
36077745Demonstrating Tumor Vascular Disrupting Activity of the Small-Molecule Dihydronaphthalene Tubulin-Binding Agent OXi6196 as a Potential Therapeutic for Cancer Treatment.Cancers (Basel)2022https://conductscience.org/library/papers/36077745PubMed
35295719Microtubule Organization Is Essential for Maintaining Cellular Morphology and Function.Oxid Med Cell Longev2022https://conductscience.org/library/papers/35295719PubMed
35215299Nitroaromatic Hypoxia-Activated Prodrugs for Cancer Therapy.Pharmaceuticals (Basel)2022https://conductscience.org/library/papers/35215299PubMed
34638255Imaging-Guided Evaluation of the Novel Small-Molecule Benzosuberene Tubulin-Binding Agent KGP265 as a Potential Therapeutic Agent for Cancer Treatment.Cancers (Basel)2021https://conductscience.org/library/papers/34638255PubMed
34326502Therapeutic targeting of the hypoxic tumour microenvironment.Nat Rev Clin Oncol2021https://conductscience.org/library/papers/34326502PubMed
33925707Non-Invasive Evaluation of Acute Effects of Tubulin Binding Agents: A Review of Imaging Vascular Disruption in Tumors.Molecules2021https://conductscience.org/library/papers/33925707PubMed
33262127Preclinical Applications of Multi-Platform Imaging in Animal Models of Cancer.Cancer Res2021https://conductscience.org/library/papers/33262127PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CA4762PubTator's text mininghttps://conductscience.org/library/genes/762NCBI Gene
POR5447PubTator's text mininghttps://conductscience.org/library/genes/5447NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32196334

GET https://conductscience.org/api/papers/v1/32196334/references?page=2